<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135028</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-429-4104</org_study_id>
    <nct_id>NCT03135028</nct_id>
  </id_info>
  <brief_title>Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults</brief_title>
  <acronym>Japanese AML</acronym>
  <official_title>A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Entospletinib (ENTO) as Monotherapy in Japanese Subjects With Relapsed or Refractory Hematologic Malignancies and in Combination With Chemotherapy in Japanese Subjects With Previously Untreated Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of
      Entospletinib (ENTO) monotherapy and in combination with chemotherapy in Japanese
      participants
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 18, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Actual">December 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Laboratory Abnormalities Defined as dose limiting toxicities (DLT)</measure>
    <time_frame>Up to Cycle 1 Day 28 with expansion to 8 weeks after Cycle 1 Day 1 in the arm of combination treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Laboratory Abnormalities Not Defined as dose limiting toxicities (DLT)</measure>
    <time_frame>Up to 30 days after permanent discontinuation of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCtau of entospletinib</measure>
    <time_frame>Predose and 2 hours Postdose</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Cmax of entospletinib</measure>
    <time_frame>Predose and 2 hours Postdose</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Tmax of entospletinib</measure>
    <time_frame>Predose and 2 hours Postdose</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: t1/2 of entospletinib</measure>
    <time_frame>Predose and 2 hours Postdose</time_frame>
    <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Ctau of entospletinib</measure>
    <time_frame>Predose and 2 hours Postdose</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hematologic Malignancy</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Entospletinib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed or refractory hematologic malignancies will receive entospletinib twice daily (BID) of every 28 day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entospletinib + cytarabine + daunorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lead-in (Cycle 0): Participants with previously untreated AML will receive entospletinib BID for 14 days
Induction (Up to 2 cycles): Entospletinib in combination with daunorubicin and cytarabine for up to two 28 day cycles
Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants will have the option to receive post-remission therapy with entospletinib BID in combination with high-dose cytarabine (Hi-DAC) for up to four 28 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>400 mg tablet (s) orally twice daily</description>
    <arm_group_label>Entospletinib Monotherapy</arm_group_label>
    <arm_group_label>Entospletinib + cytarabine + daunorubicin</arm_group_label>
    <other_name>GS-9973</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>60 mg/m^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle</description>
    <arm_group_label>Entospletinib + cytarabine + daunorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>100 mg/m^2 intravenous (IV) administration twice daily on Days 1 to 7 of each 28-day induction cycle
3g/m^2 IV administration twice daily on days 1, 3 and 5 (&lt;=60 years of age) or 1g/m^2 IV administration once daily on days 1-5 (&gt;60 years of age) of each 28-day post-remission cycle (Hi-DAC)</description>
    <arm_group_label>Entospletinib + cytarabine + daunorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Group A ENTO monotherapy: relapsed or refractory hematologic malignancies by World
             Health Organisation (WHO) criteria and who are not eligible to receive standard of
             care

          -  Group B ENTO + cytarabine + daunorubicin: previously untreated AML by WHO criteria,
             who are deemed fit for cytarabine and daunorubicin (7+3) induction chemotherapy and
             are able to undergo up to 2 cycles of induction chemotherapy, as determined by the
             treating physician

          -  Must have been born in Japan and must not have lived outside of Japan for a period &gt; 1
             year in the 5 years prior to Day 1 of study treatment

          -  Must be able to confirm the Japanese origin of their maternal and paternal ancestry

        Key Exclusion Criteria:

          -  Known active central nervous system or leptomeningeal leukemic involvement

          -  Ongoing liver injury, known chronic active hepatitis C Virus (HCV), chronic active
             hepatitis B Virus (HBV)

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Tokyo</city>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>ÅŒsaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

